

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_82943
Title of the Manuscript:	Effect of Polymorphisms in Drug Transporters on Cisplatin efficacy and nephrotoxicity in paediatric Osteosarcoma
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	D. P. Carpenter, Reputation and power : organizational image and pharmaceutical regulation at the FDA. Princeton University Press, 2010. Was not found inside the article.	This part was added (Cisplatin was approved in the United States for cancer treatment after deep research and considered as the first platinum-based compound approved by Food and Drug Administration (FDA).[3])
Minor REVISION comments	It needs little revision for the English language	English language was checked
Optional/General comments	-	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	This study was approved by the Institutional Reviewing Board of Children's Cancer Hospital-57357. All patients' guardians signed a written document of informed consent approved from the ethical committee before enrolment in the study.